Advancing Therapies for Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, and systemic lupus erythematosus (SLE), impact over 200 million people worldwide, leading to chronic pain, organ damage, and reduced quality of life. Advances in immunology, particularly in biologics and precision medicine, are transforming the therapeutic landscape. Breakthroughs such as targeted therapies, novel modalities, and cutting-edge technologies, including biomarker-driven treatments, microbiome modulation, and cell and gene therapies, are reshaping the future of care. Despite challenges like treatment accessibility and patient heterogeneity, the field is poised for continued innovation and growth, promising significant improvements in disease management and patient outcomes.

Inflammatory diseases represent a substantial burden on global health, affecting millions of individuals across diverse demographics and geographies. These diseases arise from dysregulated immune responses that lead to chronic inflammation, tissue damage, and systemic complications. Despite significant advancements in treatment options, these conditions remain incurable, underscoring the need for innovative approaches and comprehensive strategies. In recent decades, the field of immunology has witnessed groundbreaking developments. The transition from broad-spectrum immunosuppressants to highly targeted therapies has revolutionized patient care. Biologics targeting specific cytokines, small molecule inhibitors, and emerging modalities like bispecific antibodies and oral biologics are enabling more precise and effective treatments. Furthermore, novel technologies, including microbiome-based therapies and gene editing, are offering new avenues for addressing the root causes of immune dysregulation.

This article explores the evolution of inflammatory disease treatments, highlighting historical milestones, emerging innovations, and the challenges and opportunities that lie ahead. By understanding these developments, stakeholders across the healthcare spectrum can better navigate the dynamic landscape of immunology and inflammatory care.

What Are Inflammatory Diseases? – Inflammatory diseases encompass a wide range of conditions driven by dysregulated immune responses, leading to chronic inflammation and tissue damage.

Common examples include:

• Rheumatoid Arthritis (RA): An autoimmune disorder causing joint inflammation, pain, and deformity.
• Inflammatory Bowel Disease (IBD): Encompasses Crohn’s disease and ulcerative colitis, characterized by gastrointestinal inflammation.
• Psoriasis: A skin condition marked by scaly patches and systemic inflammation.
• Systemic Lupus Erythematosus (SLE): A multi-system autoimmune disease affecting the skin, joints, kidneys, and other organs.

Despite differences in presentation, these diseases share common pathways, such as cytokine dysregulation, making targeted immune modulation a promising therapeutic strategy.

Historical Context and Development – Immune-mediated inflammatory diseases are both common
and clinically diverse. Although they are currently incurable, the therapeutic armamentarium for these diseases has been transformed over the past two decades. Treatments have progressed from the broad application of immune modulators to the routine use of agents with exquisite specificity. This shift has been driven by advances in monoclonal and molecular biotechnology, as well as highly targeted medicinal chemistry. Here we highlight key advances that have defined this progress and outline future directions:

• Early Approaches: Corticosteroids and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) provided symptom relief but often led to significant long-term side effects, such as stomach ulcers, kidney damage, and increased cardiovascular risks. NSAIDs, including ibuprofen, aspirin, and naproxen, work by inhibiting the enzyme cyclooxygenase (COX), which is essential for the production of prostaglandins, chemical messengers responsible for inflammation, pain, and fever.
  This is why advancements in targeted therapies (e.g., biologics and JAK inhibitors) have become
  increasingly important in managing inflammatory diseases with fewer systemic side effects.
• The Biologic Revolution: The 1998 approval of the first anti- Tumor Necrosis Factor (TNF) biologic, infliximab (Remicade), marked a shift toward targeted therapies, significantly improving disease management.
  TNF is a key cytokine that triggers inflammation and recruits immune cells to combat infection
  and repair tissue damage. However, excessive or prolonged TNF production can lead to chronic
  inflammation, a hallmark of autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and psoriasis. To counteract this, anti-TNF therapies [infliximab (Remicade), adalimumab (Humira), and etanercept (Enbrel)], have become essential in reducing inflammation and slowing disease progression in these conditions.
• Small Molecules and JAK Inhibitors: Traditionally, immunology treatments have been dominated by biologic therapies administered via injections or infusions. However, recent advancements are transforming the landscape with the development of oral and topical therapies that combine the efficacy of biologics with greater patient convenience. For instance, JAK inhibitors like Pfizer’s tofacitinib have expanded treatment options for patients unresponsive to biologics. Additionally, emerging oral and topical formulations are being developed for conditions such as psoriasis, ulcerative colitis, and atopic dermatitis. The late- stage immunology pipeline now includes more than a dozen promising assets featuring innovative mechanisms of action, including TYK2, S1P, TLR9, MiR-124, novel JAK inhibitors, and oral agents targeting IL-17 and IL-23. These advancements mark a significant shift toward more accessible and patient-friendly therapies in immunology.
• Emerging Therapies: Advances in immunology have introduced therapies targeting IL-17, IL- 23, and integrins, with novel modalities like bispecific antibodies and cell therapies now in development.

Recent Industry Momentum – The immunology field is experiencing robust innovation and strategic
growth, driven by emerging trends and groundbreaking acquisition and licensing deals. These agreements underscore the dynamic and collaborative nature of the immunology sector, with companies forging strategic partnerships to advance innovative treatments, expand therapeutic pipelines, and improve patient access:

Major immunology-related acquisitions in 2024:

• Roche and Poseida Therapeutics (Announced in November 2024 – Closing expected to
  complete in Q1.2025): Acquisition to enhance drug pipeline in oncology, immunology, and neurology, with an initial $1B payment and additional performance-related payments potentially raising the total to $1.5B.
• Merck & Co. and Curon Biopharmaceuticals (August 2024): A $1.3 billion deal to acquire CN201, an experimental bispecific antibody targeting B-cell diseases, with a $700 million upfront payment and up to $600M in milestone payments.
• Eli Lilly and Morphic (June 2024): A $3.2 billion deal to bolster its gastroenterology offerings, particularly in treatments for IBD.
• Gilead Sciences and CymaBay Therapeutics (March 2024): A $4.3 billion deal to enhance its pipeline with treatments targeting liver diseases, including CymaBay’s lead candidate for primary biliary cholangitis (an autoimmune disease).
• Biogen and Human Immunology Biosciences (HI-Bio) (May 2024): A $1.8 billion deal to strengthen immunology portfolio, including lead asset felzartamab for rare immune-mediated conditions, for $1.15 billion upfront and up to $650 million in potential milestone payments.
• Johnson & Johnson and Numab Therapeutics (May 2024): A $1.25 billion acquisition of Yellow Jersey Therapeutics, a subsidiary of Numab, to obtain NM26, a bispecific antibody for atopic dermatitis.
• Johnson & Johnson and Proteologix (May 2024): A $850 million deal to secure bispecific antibodies targeting immune-mediated diseases.

Major immunology-related licensing agreements in 2024:

• Sanofi and Corxel Pharmaceuticals (December 2024): Exclusive rights to develop and commercialize aficamten in Greater China (financial terms undisclosed).
• AbbVie and EvolveImmune (October 2024): Collaboration using the EVOLVE T-Cell Engager Platform for immunology (financial terms undisclosed).
• GSK and CureVac (July 2024): $1.57 billion licensing deal to develop mRNA-based therapies for immunology and other areas.
• AbbVie and FutureGen Biopharmaceutical (June 2024): AbbVie licensed FG-M701, a monoclonal antibody for inflammatory bowel disease, for $150 million upfront, with milestones up to $1.56 billion and royalties.
• AbbVie and EvolveImmune (October 2024): AbbVie partnered with EvolveImmune on next-generation biotherapeutics using the EVOLVE T-Cell Engager Platform, targeting immunology.
• Eliem and Acelyrin (June 2024): Eliem acquired non-oncology rights to TNT119 (budoprutug) from Acelyrin for up to $157.5 million, including royalties.
• Kashiv and Amneal (June 2024): Kashiv granted Amneal rights to commercialize a biosimilar to XOLAIR, an asthma and urticaria treatment, to improve access to immunology drugs.
• Bristol Myers Squibb and Repertoire Immune Medicines (April 2024): Three-year collaboration to develop tolerizing vaccines for up to three autoimmune diseases, with potential deal value up to $1.8B.

Expanding Applications and Technologies – Innovative technologies are shaping the future of immunology, enabling more precise and effective treatments. Biomarker-driven precision medicine is becoming a focal point, with TL1A inhibitors like PRA023 and RVT-3101 demonstrating improved outcomes in biomarker-positive populations during clinical trials:

Bispecific Antibodies: Bispecific antibodies are an innovative class of therapies designed to target two distinct immune pathways simultaneously, offering enhanced efficacy and reduced risk of resistance compared to traditional monoclonal antibodies. By addressing multiple inflammatory drivers within a single therapeutic modality, they are particularly promising for complex and refractory autoimmune diseases. For instance, Amgen’s AMGEVITA targets both IL-17 and TNF-alpha, two key cytokines involved in autoimmune and inflammatory conditions such as rheumatoid arthritis and psoriasis. This dual targeting approach allows for broader suppression of inflammatory pathways, addressing overlapping mechanisms of disease and potentially improving outcomes in patients who do not respond adequately to single-pathway therapies.
• Oral Biologics: Advances in oral biologics are opening new possibilities in immunology, with several promising developments. Eli Lilly is exploring oral IL-17 antagonists for autoimmune diseases like psoriasis, while Protagonist Therapeutics is developing oral peptides such as PN-235 and PN-943 targeting IL-23 and integrin pathways for inflammatory bowel disease. Rani Therapeutics’ RaniPill™ is adapting TNF-alpha inhibitors for oral delivery in conditions like rheumatoid arthritis. Additionally, Vedanta Biosciences is leveraging microbiome-derived biologics like VE416 to modulate immune pathways, and Chugai Pharmaceutical is advancing oral antibody fragment technologies for autoimmune diseases. These innovations aim to improve patient convenience and adherence, transforming treatment paradigms in immunology.
• Microbiome Modulation: Advances in microbiome research are revealing its critical role in immune regulation, driving the development of therapies that target microbial imbalances in conditions like IBD. For example, Vedanta Biosciences’ VE303, a rationally defined microbiome therapeutic, has shown promise in restoring gut flora and reducing inflammation in early trials, while Seres Therapeutics’ SER-109 has demonstrated success in correcting microbial imbalances. Concurrently, innovations in oral and topical therapies are reshaping treatment paradigms for diseases like psoriasis and atopic dermatitis. Promising late-stage assets include TYK2 inhibitors, S1P modulators, and novel IL-17 inhibitors, offering both efficacy and greater convenience for patients.
• Cell and Gene Therapy: CAR-T cell therapy, originally developed for cancer, is being explored for autoimmune diseases by reprogramming T cells to target and eliminate autoreactive immune cells, with promising early results in conditions like lupus and multiple sclerosis. Meanwhile, CRISPR gene-editing technologies aim to correct immune dysregulation at its source by modifying genes associated with autoimmunity, such as those driving inflammatory cytokine production or B-cell dysfunction. These cutting-edge approaches have the potential to shift autoimmune treatment from symptom management to addressing root causes, offering hope for durable remissions or cures, though challenges around safety, precision, and scalability remain.

Challenges and Future Opportunities – While significant progress has been made, inflammatory diseases present ongoing challenges:
• Patient Heterogeneity: Variability in disease presentation and response to treatment necessitates personalized approaches.
• Long-Term Safety: Newer therapies, such as JAK inhibitors, raise concerns about long-term risks like infection and malignancy.
• Cost and Accessibility: The high price of biologics and advanced therapies limits their accessibility, especially in low-resource settings.

Future opportunities include:

• Precision Medicine: Biomarker-driven approaches are revolutionizing the development of targeted therapies, particularly in immunology. Biomarkers such as IL-23 and TNF-alpha are now critical tools for stratifying patients and tailoring treatments. Emerging therapies, including TL1A inhibitors like Merck/Prometheus’ PRA023 and Roivant’s RVT-3101, utilize specific biomarkers to optimize patient selection in clinical trials for conditions like ulcerative colitis and Crohn’s disease. Recent Phase 2 trial results highlight significantly improvedoutcomes among biomarker-positive patients, underscoring the potential of precision medicine to deliver more effective and personalized therapies in the field of immunology.

• Combination Therapies: Pairing biologics with small molecules or microbiome-based interventions could yield synergistic benefits.

• Early Intervention: Advancements in diagnostic tools are enabling earlier detection, improving long-term outcomes.

The field of immunology is experiencing a period of profound transformation, fueled by breakthroughs in biologics, small molecules, and microbiome-based research. These innovations are redefining treatment paradigms, improving patient outcomes, and making therapies more accessible and cost-effective. By sustaining momentum and addressing persistent challenges, the field holds the potential to deliver transformative solutions that alleviate the physical and societal burdens of chronic inflammatory diseases.

Download the document here.

Author: Dr. Jean Chatellier, PhD
Partner, EVP & Managing Director
KYBORA
Email: jean@kybora.com